期刊文献+

血清CA125用于预测上皮性卵巢癌、输卵管癌及腹膜癌化疗反应性的研究 被引量:9

Study on serum CA125 level used in predicting sensitivity to chemotherapy in epithelial ovarian carcinoma,fallopian carcinoma and peritoneal carcinoma patients
下载PDF
导出
摘要 目的:探讨上皮性卵巢癌、输卵管癌及腹膜癌对铂类+紫杉醇类化疗敏感性与CA125变化的关系。方法:选取2009年1月至2011年5月上海市第一妇婴保健院手术及化疗的71例上皮性卵巢癌、6例输卵管癌和1例腹膜癌患者,以3次化疗后血清CA125能否降至正常(<35kU/L),术后前3次化疗后每次CA125同上次比较能否降低50%作为判断铂类敏感的指标,比较分析化疗敏感型患者CA125数值变化规律。结果:(1)术前CA125数值对于判断患者第2次及第3次化疗后血清CA125能否下降50%以上具有统计学意义(P<0.01);(2)术后首次CA125数值对于判断患者第2次(P=0.028),第3次(P<0.01)化疗后血清CA125能否下降50%,以及3次化疗后血清CA125能否降至正常(P=0.046)具有统计学意义;(3)较早FIGO分期(FIGOⅠ~Ⅱ期),无腹水,满意的肿瘤灭减术也是决定患者化疗敏感性的临床指标。结论:术前和术后血清CA125水平、较早的FIGO分期、无腹水、满意的肿瘤减灭术是影响卵巢癌、输卵管癌、腹膜癌患者化疗敏感性的有意义的临床指标。 Objective:To investigate the relationship between serum CA125 changes and response to chemotherapy based on platinum in epithelial ovarian carcinoma,fallopian carcinoma and peritoneal carcinoma patients.Methods:From Jan.2009 to May 2011,78 patients with epithelial ovarian carcinoma,fallopian carcinoma and peritoneal carcinoma undergoing treatment in Shanghai First maternity infant hospital were studied retrospectively.The level of serum CA125 dropped to less than 35kU/L after 3 cycles or dropped down more than 50% after each cycle were considered as chemotherapy sensitivity to compound of taxane+platinum.Those changes of CA125 were compared with clinical parameters.Results:(1) Pre-operative serum CA125 could predict whether the level of serum CA125 would drop down more than 50% after second and third cycle of chemotherapy(P0.01).(2)Postoperative serum CA125 could predict whether the level of serum CA125 would drop down more than 50% after second(P=0.028) and third cycle of chemotherapy(P0.01).(3) Early FIGO stage(FIGOⅠ~Ⅱ),ascites fluid and optimal cytoreduction were also associated with the sensitivity to paclitaxel/carboplatin chemotherapy.Conclusions:Pre-and post-operative serum CA125,early FIGO stage,ascites fluid and optimal cytoreduction are clinical useful variables to predict sensitivity to paclitaxel/carboplatin.
出处 《现代妇产科进展》 CSCD 2012年第8期596-599,共4页 Progress in Obstetrics and Gynecology
基金 上海市科委课题资助(No:10411969200)
关键词 卵巢肿瘤 CA125抗原 血清 输卵管肿瘤 腹膜肿瘤 药物疗法 抗药性 肿瘤 Ovarian neoplasms CA125 antigen Serum Fallopian tube neoplasms Peritoneal neoplasms Drug therapy Drug resistance neoplasm
  • 相关文献

参考文献12

  • 1Burges A,Schmalfeldt B.Ovarian cancer:diagnosis andtreatment[J]Dtsch Arztebl Int,2011,108(38):635-641.
  • 2Riedinger JM,Eche N,Basuyau JP,et al.Prognostic valueof serum CA 125 bi-exponential decrease during first linepaclitaxel/platinum chemotherapy:a French multicentricstudy[J].Gynecol Oncol,2008,109(2):194-198.
  • 3蓝春燕,黄鹤,刘继红.晚期卵巢上皮性癌患者初次治疗过程中血清CA125水平变化与其预后的关系[J].中华妇产科杂志,2008,43(10):732-736. 被引量:7
  • 4Hogdall E.Cancer antigen 125 and prognosis[J].CurrOpin Obstet Gynecol,2008,20(1):4-8.
  • 5Petri AL,Hogdall E,Christensen IJ,et al.PreoperativeCA125 as a prognostic factor in stage I epithelial ovariancancer[J].APMIS,2006,114(5):359-363.
  • 6Osman N,O'Leary N,Mulcahy E,et al.Correlation of ser-um CA125 with stage,grade and survival of patients withepithelial ovarian cancer at a single centre[J].Ir Med J,2008,101(8):245-247.
  • 7Markmann S,Gerber B,Briese V.Prognostic value of Ca125 levels during primary therapy[J].Anticancer Res,2007,27(4A):1837-1839.
  • 8Markman M,Federico M,Liu PY,et al.Significance ofearly changes in the serum CA-125 antigen level on over-all survival in advanced ovarian cancer[J].Gynecol On-col,2006,103(1):195-198.
  • 9Hogdall EV,Christensen L,Kjaer SK,et al.CA125 ex-pression pattern,prognosis and correlation with serumCA125 in ovarian tumor patients.From The Danish‘MALOVA’Ovarian Cancer Study[J].Gynecol Oncol,2007,104(3):508-515.
  • 10Riedinger JM,Wafflart J,Ricolleau G,et al.CA 125half-life and CA 125 nadir during induction chemothera-py are independent predictors of epithelialovarian canc-er outcome:results of a French multicentric study[J].Ann Oncol,2006,17(8):1234-1238.

二级参考文献17

  • 1Piccart M J, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer : three-year resuhs. J Nail Cancer lnst,2000,92:699-708.
  • 2Brun JL, Feyler A, Chene G, et al. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol 0ncol,2000,78:21-27.
  • 3Markman M, Bundy BN, Alberts DS, et al. Phase Ⅲ trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smaU-volume stage Ⅲ ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Onco1,2001,19 : 1001-1007.
  • 4Bast RC Jr, Klug TL, St John E,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med,1983,309:883-887.
  • 5Kenemans P, Yedema CA, Bon GG, et al. CA125 in gynecological pathology: a review. Eur J Obstet Gynecol Reprod Biol, 1993,49 : 115-124.
  • 6Cooper BC, Sood AK, Davis CS, et al. Preoperative CA125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol,2002,100:59-64.
  • 7van Dalen A, Favier J, Burges A, et al. Prognostic significance of CA125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol,2000,79:444-450.
  • 8Markman M, Federico M, Liu PY, et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol,2006,103:195-198.
  • 9Colakovic S, Lukic V, Mitrovic L, et al. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers ,2000,15 : 147-152.
  • 10Buller RE, Berman ML, Bloss JD, et al. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol, 1992,47:87-92.

共引文献6

同被引文献101

引证文献9

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部